Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05920252 · ClinicalTrials.gov registry record · NA
A Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide
A NA study of Suicide and Anhedonia, sponsored by Ksana Health.
- Recruiting
- Registry status
- NA
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT05920252: Recruiting NA study of Suicide and Anhedonia, sponsored by Ksana Health.
NCT05920252 is a NA study of Suicide and Anhedonia that is actively recruiting participants, run by Ksana Health. The registered enrollment target is 78 participants, below the 6,989-participant average among 92 other Suicide trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05920252, a NA study of Suicide and Anhedonia, is actively recruiting participants, sponsored by Ksana Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death among youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be used to provide a unique understanding of risk factors, including psychological distress, anhedonia and behavioral withdrawal, and sleep disturbance among high-risk individuals. This project aims to enhance the effectiveness of the delivery of preventative health care to youth at risk for suicide by developing a comprehensive digital platform that allows practitioners to integrate mobile sensing data and HIPAA-compliant client communication tools into their management of these young people.
Primary Outcome
The C-SSRS is an assessment of suicidal thoughts and behaviors in clinical and research settings. The C-SSRS consists of 16 questions about suicidal thoughts and behaviors (the first 10 questions comprise the ideation subscale and the last 6 comprise the behavior subscale). This 5-item subscale ranges from a minimum of 0 (corresponding to no suicidal ideation) to a maximum of 5 (representing active suicidal ideation with plan and intent).
Conditions Studied
Interventions
- BEHAVIORAL Treatment as Usual (TAU)
- BEHAVIORAL Vira
Study Locations (1)
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT05920252 shows while recruiting
NCT05920252 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 6,989-participant average among 92 other Suicide trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Suicide appearing as the primary indexed condition, and to 2 interventions - of which Treatment as Usual (TAU) is the first listed.
NCT05920252 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05920252 about?
NCT05920252 is a clinical study titled "A Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide". Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death among youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be used to provide a unique understanding of risk factors, including psycholo...
What is the current status of trial NCT05920252?
This trial is currently recruiting. It is a NA study. The enrollment target is 78 participants. The study started on 2024-08-14. Estimated completion is 2026-12-31.
What conditions does trial NCT05920252 study?
This clinical trial studies the following conditions: Suicide, Anhedonia, Mental Health Disorder.
What interventions are being tested in trial NCT05920252?
The interventions under investigation include: Treatment as Usual (TAU) (BEHAVIORAL), Vira (BEHAVIORAL).
Who is sponsoring clinical trial NCT05920252?
This trial is sponsored by Ksana Health, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05920252 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Suicide
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05920252's enrollment target sits among peer trials
78 57th of 92 higher than 36 of 92 other Suicide trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Suicide trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Randomized Clinical Trial of Supplementing Brief Psychotherapy With a Mobile App
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
-
Suicide Specific Rumination in Veterans
RECRUITING · NA
-
Real-time Examination of Skills and Coping Use in Teen's Everyday Lives
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI